- Home
- NXTC vs INBS Comparison
NXTC vs INBS Comparison
Compare NXTC & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- INBS
- Stock Information
- Founded
- NXTC 2015
- INBS 2016
- Country
- NXTC United States
- INBS United States
- Employees
- NXTC N/A
- INBS N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- INBS Medical Specialities
- Sector
- NXTC Health Care
- INBS Health Care
- Exchange
- NXTC Nasdaq
- INBS Nasdaq
- Market Cap
- NXTC 13.0M
- INBS 11.7M
- IPO Year
- NXTC 2019
- INBS N/A
- Fundamental
- Price
- NXTC $10.77
- INBS $1.09
- Analyst Decision
- NXTC Strong Buy
- INBS
- Analyst Count
- NXTC 2
- INBS 0
- Target Price
- NXTC $25.50
- INBS N/A
- AVG Volume (30 Days)
- NXTC 49.2K
- INBS 181.5K
- Earning Date
- NXTC 11-06-2025
- INBS 11-06-2025
- Dividend Yield
- NXTC N/A
- INBS N/A
- EPS Growth
- NXTC N/A
- INBS N/A
- EPS
- NXTC N/A
- INBS N/A
- Revenue
- NXTC N/A
- INBS $3,052,532.00
- Revenue This Year
- NXTC N/A
- INBS $778.48
- Revenue Next Year
- NXTC N/A
- INBS N/A
- P/E Ratio
- NXTC N/A
- INBS N/A
- Revenue Growth
- NXTC N/A
- INBS N/A
- 52 Week Low
- NXTC $2.69
- INBS $1.01
- 52 Week High
- NXTC $19.20
- INBS $2.75
- Technical
- Relative Strength Index (RSI)
- NXTC 77.64
- INBS 41.09
- Support Level
- NXTC $6.23
- INBS $1.01
- Resistance Level
- NXTC $13.17
- INBS $1.17
- Average True Range (ATR)
- NXTC 0.91
- INBS 0.06
- MACD
- NXTC 0.50
- INBS 0.01
- Stochastic Oscillator
- NXTC 67.51
- INBS 53.13
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).